ukrain - antikanker medicijn ?


logo.jpg (7231 bytes)

Google

 

Ukrain - anti kanker medicijn ?

Een professor uit de Ukraine claimt een zeer interessant antikanker medicijn te hebben gevonden. Het middel Ukrain is ontwikkeld uit stoffen uit de plant Chelidonium majus L. (Stinkende gouwe) en het medicijn Thiotepa. Beide ingrediënten zijn goedgekeurde medicijnen en worden klinisch gebruikt.

stinkendegouwe - Prof. Dr. Otto Wilhelm Thomé 1885

Echter Ukrain is minder toxisch dan de losse ingrediënten maar heeft gelijkertijd een sterkere anti-kanker werking.

Ik hoop dat Nederlandse wetenschappers eens serieus willen kijken naar onderstaande onderzoeken die gedaan zijn op dit gebied.

Een uitgebreide lijst van studies vind je hier:

http://www.ukrin.com/Ref/iccref1.html

Informatie in het Nederlands - klik hier

Contact gegevens van deze onderzoeker

Dr. Wassil Nowicky
Margaretenstr. 7
A-1040 Vienna
Austria
Tel: (+43 1) 586 12 23
Fax: (+43 1) 586 89 94
Email: nowicky@ukrin.com

De sites:

Verder hebben collega's hem op een Spaanse conferentie over alternatieve behandelingen tegen kanker genomineerd voor een Nobel prijs (Chemie):

During the presentation by Dr Jaroslaw W. Nowicky, Director of the Ukrainian Anti-Cancer Institute of Vienna (Austria), the congress organizers announced his nomination by colleagues for the Nobel Prize in Chemistry. When it is injected intravenously in therapeutic doses, Ukrain destroys carcinogenic cells by stimulating their ‘suicide’ or apoptosis without affecting healthy cells. Ukrain has been the object of investigations and studies by 159 scientists from 56 universities in 26 different countries. Results have been presented in 220 international scientific congresses and symposia. Details of the properties of Ukrain have been published in 192 scientific publications.

Source: http://ecam.oxfordjournals.org/cgi/content/full/2/3/411

Waarom veel kanker oplossingen niet op de markt komen, lees dit boek
van Eleonore Thun-Hohenstein maar eens:

In de database van de Amerikaanse overheid vond ik dit onderzoek:

Retrospective study of Ukrain treatment in 203 patients with advanced-stage tumors.

Aschhoff B. Villa Medica Clinic, Edenkoben, Germany.

A total of 203 advanced-stage cancer patients suffering from different types of cancer who had exhausted all conventional forms of therapy were treated with the novel antitumor drug Ukrain over a period of 2.5 years at the Villa Medica Clinic in Germany. Seventy-six patients (37.4%) were simultaneously treated with regional deep hyperthermia in which tumor tissue was heated to > 42.5 degrees C. Patients also received complementary oncological treatment with selen, cimetidine, thyme extract and vitamin A. In view of the advanced stage of the disease, the results of therapy were surprising. Forty-one patients (20.2%) achieved total remission, 122 (60.1%) partial remission and only 40 (19.7%) did not respond to treatment. The highest response rates were in patients with seminoma (three out of four patients had total remission and one had partial remission) and in prostate cancer [14 out of 20 patients (70%) achieved total remissions and five achieved partial remission].

Drugs Exp Clin Res. 2000;26(5-6):249-52

Url: http://www.ncbi.nlm.nih.gov/

De resultaten:

Results of Ukrain therapy in patients with various
advanced-stage cancers

Type of tumor (according to frequency) N Full remission % Partial remission % No influence%
1 Colorectal cancer 31 16.1 71 12.9
2 Breast cancer 25 28 64 8
3 Prostate cancer 20 70 25 5
4 Small-cell lung cancer 8 12.5 75 12.5
5 Ewing's sarcoma 7 57.1 42.9 0
6 Osteogenic sarcoma 7 71.5 28.5
7 Signet ring-cell cancer 7 85.7 14.3
8 Pancreas cancer 7 85.7 14.3
9 Stomach cancer 6 16.6 66.6 16.6
10 Squamous cell cancer 6 83.3 16.6
11 Gall bladder cancer 6 100
12 Neuroblastoma 5 60 20 20
13 Ovarian cancer 5 20 80
14 Seminoma 4 75 25
15 Nephroblastoma 4 25 75
16 Glioblastoma 4 75 25
17 Lung adeno cancer 4 50 50
18 Vulva-cervical cancer 4 100
19 Malignant melanoma 4 75 25
20 Astrocytoma 3 33.3 33.3 33.3
21 Unknown genesis 3 33.3 66.6
22 Rhabdomyo sarcoma 3 33.3 66.6
23 Medulloblastoma 3 66.6 33.3
24 Non-Hodgkin's lymphoma 3 66.6 33.3
25 Pleura-mesothelioma 2 66.6
Total 203 20.2 60.1 19.7

National Cancer Institute, Bethesda, Maryland, USA

Almost all cancer cell lines demonstrated growth inhibition of between 50% and 100%, which, at higher concentrations (50µg/ml) turned into a cytolytic effect with a reduction of total cell mass.

The highest concentration of Ukrain (50µg/ml) inhibited the proliferation of normal cells (endothelial cells, fibroblasts, keratinocytes, prostate epithelial cells) without any cytotoxic effect.

The chemotherapeutic compound, 5-Fluorouracil, which was investigated under identical conditions, completely inhibited growth only in a few cell lines under extremely high concentrations (500µg/ml), while a reduction in cell mass was never observed.

Ukrainian Anti-Cancer Institute

The Ukrainian Anti-Cancer Institute (UACI) is a non-profit organization dedicated to free and independent scientific research on Ukrain®. To the present day 16 countries have participated in the UACI research with more than 150 scientists in 46 universities and research institutes.
The results of UACI research are regularly presented on international congresses and published in scientific magazines. In June 1997 alone a total of 31 presentations were held on three international congresses.

Many collaborating scientists have received high honours among others:

- Community Association of European Order of Merit - Diplome d'honeur
- Eureka Ehrenpreis der Albert Schweitzer Gesellschaft

- Membership of the New York Academy of Science

- Accademia Universale "Guglielmo Marconi", Arti tellere Scienze - ROMA

- Cruz de Oficial al Mérito Belgo-Hispanica, Asociatión Belgo-Hispanico

- Bona fide Member of the International Order of Merit, The International Biographical Centre Cambridge

- (in addition to the scientific doctorate) Doctor honoris causa

Links

http://www.yarmoluk.org.ua/uan/uan.html

http://www.ukrin.com/

Ukrain - a new cancer cure?

A systematic review of randomised clinical trials.

Ukrain is an anticancer drug based on the extract of the plant Chelidonium majus L. Numerous pre-clinical and clinical investigations seem to suggest that Ukrain is pharmacologically active and clinically effective. We wanted therefore to critically evaluate the clinical trial data in the form of a systematic review.

CONCLUSION: The data from randomised clinical trials suggest Ukrain to have potential as an anticancer drug. However, numerous caveats prevent a positive conclusion, and independent rigorous studies are urgently needed.

Ernst E, Schmidt K. Complementary Medicine, Peninsula Medical School, Universities of Exeter & Plymouth, 25 Victoria Park Road, Exeter EX2 4NT. edzard.ernst@pms.ac.uk - BMC Cancer. 2005 Jul 1;5(1):69

Full article here

Meer studies

  • Nowicky J, Greif M, Hamler F, Hiesmayr W, Staub W. Biological activity of ukrain in vitro and in vivo. Chemioterapia. 1987;6:683–5. [PubMed]
  • Hohenwarter O, Strutzenberger K, Katinger H, Liepins A, Nowicky JW. Selective inhibition of in vitro cell growth by the anti-tumour drug Ukrain. Drugs Exp Clin Res. 1992;18:1–4. [PubMed]
  • Bruller W. Studies concerning the effect of Ukrain in vivo and in vitro. Drugs Exp Clin Res. 1992;18:13–6. [PubMed]
  • Slesak B, Nowicky JW, Harlozinska A. In vitro effects of Chelidonium majus L. alkaloid thiophosphoric acid conjugates (Ukrain) on the phenotype of normal human lymphocytes. Drugs Exp Clin Res. 1992;18:17–21. [PubMed]
  • Chlopkiewicz B, Marczewska J, Ejchart A, Anuszewska E, Koziorowska J. Evaluation of mutagenic, genotoxic and transofrming properties of Ukrain. Drugs Exp Clin Res. 1992;18:31–4. [PubMed]
  • Sotomayor EM, Rao K, Lopez DM, Liepins A. Enhancement of macrophage tumouricidal activity by the alkaloid derivative Ukrain. In vitro and in vivo studies. Drugs Exp Clin Res. 1992;18:5–11. [PubMed]
  • Staniszewski A, Slesak B, Kolodziej J, Harlozinska-Szmyrka A, Nowicky JW. Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid alkaloid derivatives from Chelidonium majus L. (Ukrain). Drugs Exp Clin Res. 1992;18:63–7. [PubMed]
  • Kleinrok Z, Jagiello-Wojtowicz E, Matuszek B, Chodkowska A. Basic central pharmacological properties of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. Pol J Pharmacol Pharm. 1992;44:227–39. [PubMed]
  • Thakur ML, DeFulvio J, Tong J, John E, McDevitt MR, Damjanov I. Evaluation of biological response modifiers in the enhancement of tumor uptake of technetium-99 m labeled macromolecules. A preliminary report. J Immunol Methods. 1992;152:209–16. doi: 10.1016/0022-1759(92)90142-G. [PubMed] [Full Text]
  • Liepins A, Nowicky JW. Activation of spleen cell lytic activity by the alkaloid thiophosphoric acid derivative: Ukrain. Int J Immunopharmacol. 1992;14:1437–42. doi: 10.1016/0192-0561(92)90016-E. [PubMed]
  • Jodlowska-Jedrych B. Morphological studies on rat's liver after a ten-day treatment with Chelidonium majus L. alkaloid thiophosphoric acid derivative (Ukrain). Ann Univ Mariae Curie Sklodowska [Med]. 1994;49:119–24. [PubMed]
  • Liepins A, Nowicky JW, Bustamente JO, Lam E. Induction of bimodal programmed cell death in malignant cells by the derivative Ukrain (NSC-631570). Drugs Exp Clin Res. 1996;22:73–9. [PubMed]
  • Nowicky JW, Hiesmayr W, Nowicky W, Liepins A. Influence of Ukrain on DNA, RNA and protein synthesis in malignant cells. Drugs Exp Clin Res. 1996;22:81–91. [PubMed]
  • Nowicky JW, Hiesmayr W, Nowicky W, Liepins A. Influence of Ukrain on human xenografts in vitro. Drugs Exp Clin Res. 1996;22:93–7. [PubMed]
  • Jin JM, Nowicky JW, Liepins A. Mitogenic properties of Ukrain (NSC-6315170) on human peripheral blood monocytes: clinical implications. Drugs Exp Clin Res. 1996;22:99–101. [PubMed]
  • Liepins A, Nowicky JW. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570). Drugs Exp Clin Res. 1996;22:103–13. [PubMed]
  • Susak YM, Kurik MV, Kravchenko OV, Zemskov SV. Certain biophysical properties of Ukrain. Drugs Exp Clin Res. 1996;22:185–7. [PubMed]
  • Zhalilo LI, Susak YM, Zemskov SV, Susak IA. Influence of Ukrain on the redox processes of hepatocytes. Drugs Exp Clin Res. 1996;22:189–91. [PubMed]
  • Brzosko WJ, Graczyk A, Konarski J, Nowicky JW. Synergic influence of Ukrain and photoporphyrin amino acid conjugates on human malignant cell lines. Drugs Exp Clin Res. 1996;22:193–4. [PubMed]
  • Ciebiada I, Korczak E, Nowicky JW, Denys A. Estimation of direct influence of Ukrain preparation on influenza viruses and the bacteria E. coli and S. aureus. Drugs Exp Clin Res. 1996;22:219–23. [PubMed]
  • Voltchek I, Kamyshentsev M, Lavinsky Y, Nowicky J, Medvedev Y, Litvinchuk L. Comparative study of the cytostatic effects of Oliphen and Ukrain. J Chemother. 1996;8:144–6. [PubMed]
  • Korolenko TA, Kaledin VI, Svechnikova IG, Li XV, Stashko JF, Ilnitskaya SI, et al. Study of the antitumour effect of Ukrain: the role of macrpphage secretion of alpha-1-proteinase inhibitor. Drugs Exp Clin Res. 1998;24:271–6. [PubMed]
  • Kulik GI. Comparative in vitro study of the effects of the new antitumour drug Ukrain and several cytostatic agents on the thiol groups in the tissue of Guerin carcinoma and its resistance to cisplatin variant. Drugs Exp Clin Res. 1998;24:277–80. [PubMed]
  • Boyko VN, Belskiy SN. The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect. Drugs Exp Clin Res. 1998;24:335–7. [PubMed]
  • Panzer A, Hamel E, Joubert AM, Bianchi PC, Seegers JC. Ukrain™, a semisynthetic Chelidonium majus alkaloid derivative, acts by inhibition of tubulin polymerization in normal and malignant cell lines. Cancer Lett. 2000;160:149–57. doi: 10.1016/S0304-3835(00)00578-4. [PubMed] [Full Text]
  • Panzer A, Joubert AM, Eloff JN, Albrecht CF, Erasmus E, Seegers JC. Chemical analyses of Ukrain, a semi-synthetic Chelidonium majus alkaloid derivative, fail to confirm its trimeric structure. Cancer Lett. 2000;160:237–41. doi: 10.1016/S0304-3835(00)00595-4. [PubMed] [Full Text]
  • Roublevskaia IN, Polevoda BV, Ludlow JW, Haake AR. Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug Ukrain. Anticancer Res. 2000;20:3163–7. [PubMed]
  • Panzer A, Joubert AM, Bianchi PC, Seegers JC. The antimitotic effects of Ukrain, a Chelidonium majus alkaloid derivative, are reversible in vitro. Cancer Lett. 2000;150:85–92. doi: 10.1016/S0304-3835(99)00375-4. [PubMed] [Full Text]
  • Panzer A, Joubert AM, Bianchi PC, Hamel E, Seegers JC. The effects of chelidonine on tubulin polymerisation, cell cycle progression and selected signal transmission pathways. Eur J Cell Biol. 2001;80:111–8. [PubMed]
  • Roublevskaia IN, Haake AR, Ludlow JW, Polevoda BV. Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. Drugs Exp Clin Res. 2000;26:141–7. [PubMed]
  • Roublevskaia IN, Haake AR, Polevoda BV. Bcl-2 overexpression protects human keratinocyte cells from Ukrain-induced apoptosis but not from G2/M arrest. Drugs Exp Clin Res. 2000;26:149–56. [PubMed]
  • Voltchek I, Sologub T, Nowicky JW, Grigoryeva T, Belozyorova L, Belopolskaya M, et al. Preliminary results of individual therapy of chronic hepatitis C by Ukrain and interferon-alpha. Drugs Exp Clin Res. 2000;26:261–6. [PubMed]
  • Votrin II, Voltchek IV, Kurochkin SN, Kolobkov SL. Effects of Ukrain on the activities of DNA-nicking enzymes. Drugs Exp Clin Res. 2000;26:267–73. [PubMed]
  • Jagiello-Wojtowicz E, Dudka J, Dawidek-Pietryka K. Effect of Ukrain on human liver alcohol dehydrogenase activity in vitro. Drugs Exp Clin Res. 2000;26:337–9. [PubMed]
  • Kuznetsova LP, Nikol'skaia EB, Sochilina EE, Faddeeva MD. The inhibition enzymatic hydrolysis of acetylthiocholine by acetylcholinesterase using principle alkaloids isolatted from celandine and macleya and their derivatives. Tsitologiia. 2001;43:1046–50. [PubMed]
  • Cordes N, Blaese MA, Plasswilm L, Rodemann HP, Van Beuningen D. Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells in vitro. Int J Radiat Biol. 2003;79:709–20. doi: 10.1080/09553000310001610240. [PubMed] [Full Text]
  • Kleinrok Z, Jagiello-Wojtowicz E, Nowicky JW, Chodkowska A, Feldo M, Matusek B. Some pharmacological properties of prolonged administration of Ukrain in rodents. Drugs Exp Clin Res. 1992;18:93–6. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Chodkowska A, Feldo M, Nowicky JW. Modification of antinociceptive action of morphine by Ukrain in rodents. Drugs Exp Clin Res. 1992;18:101–5. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Feldo M, Chodkowska A, Nowicky JW. Effect of Ukrain on the efficacy of anti-epileptic drugs against maximal electroshock-induced seizures in mice. Drugs Exp Clin Res. 1992;18:107–9. [PubMed]
  • Juszkiewicz T, Minta M, Wlodarczyk B, Biernacki B. Teratological evaluation of Ukrain in hamsters and rats. Drugs Exp Clin Res. 1992;18:23–9. [PubMed]
  • Wyczolkowska J, Czuwaj M, Maslinski C. The immunomodulating preparation Ukrain does not induce anaphylactic sensitization in mice and guinea pigs. Drugs Exp Clin Res. 1992;18:35–8. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Matuszek B, Surmaczynska B, Baran E, Nowicky W, et al. Effect of three months treatment with Ukrain on peripheral blood morphology in rodents. Drugs Exp Clin Res. 1992;18:79–83. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Surmaczynska B, Baran E, Feldo M, Nowicky JW. Effect of single and three months treatment with Ukrain on aminotransferases (ALT and AST) and on the serum protein level in rodents. Drugs Exp Clin Res. 1992;18:85–7. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Nowicky JW, Matuszek B, Baran E, Surmaczynska B. Effect of single and prolonged administration of Ukrain on prolactin concentration in rats. Drugs Exp Clin Res. 1992;18:89–91. [PubMed]
  • Matysek M, Krolikowska-Prasal I, Jedrych B. Histological appreciation of the stomach after the application of thiophosphoric acid derivatives of Chelidonium majus L. (Ukrain) alkaloids. Ann Univ Mariae Curie Sklodowska. 1992;47:123–6.
  • Ciebiada I, Korczak E, Denys A, Nowicky JW. Effect of Ukrain preparation on immune response in mice affected by influenza virus. J Chemother. 1995;7:101–4. [PubMed]
  • Boyko VN, Voltchek IV, Petrov AS, Bubneov VP. Action of Ukrain, a cytostatic and immunomodulating drug, on effects of irradiation. Drugs Exp Clin Res. 1996;22:167–71. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Nowicky JW, Jablonski M, Gorzelak M, Chodkowska A, et al. Effect of six-month treatment with Ukrain on early osteoporosis induced by ovariectomy in rats. Part I: Preliminary studies of bone parameters. Drugs Exp Clin Res. 1996;22:173–6. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Nowicky JW, Chodkowska A, Feldo M, Surmaczynska B, et al. Effect of six-month treatment with Ukrain on early osteoporosis induced by ovariectomy in rats. Part II: Preliminary studies of peripheral blood parameters. Drugs Exp Clin Res. 1996;22:177–80. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Nowicky JW, Baran E. Effect of six-month treatment with Ukrain onearly osteoporosis induced by ovariectomy in rats. Part III: Preliminary studies of some hormone levels. Drugs Exp Clin Res. 1996;22:181–4. [PubMed]
  • Wyczolkowska J, Michon T, Nowicky JW. Inhibitory effect of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. (Ukrain) on ovalbumin antigenicity and antiovalbumin IgE antibody response in mice. Drugs Exp Clin Res. 1996;22:195–200. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Chodkowska A, Nowicky JW, Piper H, Kubiatowski T. Antinociceptive effect of ten day administration of Ukrain in mice and interaction of the treatment with morphine. Drugs Exp Clin Res. 1996;22:201–3. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Nowicky JW, Chodkowska A, Kubiatowski T, Piper H. Interaction between Ukrain and morphine in their ten-day treatment in mice in the writhing syndrome test. Drugs Exp Clin Res. 1996;22:205–6. [PubMed]
  • Ciebiada I, Korczak E, Nowicky JW, Denys A. Does the Ukrain preparation protect mice against lethal doses of bacteria? Drugs Exp Clin Res. 1996;22:207–11. [PubMed]
  • Lozjuk RM, Lisnyak OI, Lozjuk LV. Theoretical grounds and experiemntal confirmation of the antiviral effect of the preparation Ukrain. Drugs Exp Clin Res. 1996;22:213–7. [PubMed]
  • Lisnyak OI, Lozjuk RM. Biological activity of some thiophosphoric derivatives of alkaloids with respect to influenza virus. Drugs Exp Clin Res. 1996;22:225–8. [PubMed]
  • Todor IN, Kazmin SD, Susak YaM, Zemskov SV. The influence of glucose, succinate, pH of the medium and higher temperature on the cytotoxic activity of the preparation Ukrain. Drugs Exp Clin Res. 1998;24:247–52. [PubMed]
  • Korolenko TA, Svechnikova IG, Filjushina EE, Kaledin VI, Vakulin GM, Usynin IF, et al. Macrophage stimulation and antitumour effect of Ukrain. Drugs Exp Clin Res. 1998;24:253–60. [PubMed]
  • Svechnikova IG, Korolenko TA, Stashko JuF, Kaledin VI, Nikolin VP, Nowicky JW. The influence of Ukrain on the growth of HA-1 tumo rin mice: the role of cysteine proteinases as markers of tumor malignancy. Drugs Exp Clin Res. 1998;24:261–9. [PubMed]
  • Deneka ER. Morphometric and kinetic analysis of th egrowth of experimental sarcoma-45 in the presence of Ukrain. Drugs Exp Clin Res. 1998;24:281–5. [PubMed]
  • Kulik GI, Deneka ER, Todor IN, Karminozina LG. Study of acute toxicity of Ukrain in rats after intravenous injection. Drugs Exp Clin Res. 1998;24:287–93. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Feldo M, Chodkowska A, Szponar J, Urbanska EM. Six-week treatment with Ukrain in rabbits. Part I: Morphological parameters. Drugs Exp Clin Res. 1998;24:295–9. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Feldo M, Chodkowska A, Szklarczyk V, Urbanska EM. Six-week treatment with Ukrain in rabbits. Part II: Serum levels of gonadal hormones. Drugs Exp Clin Res. 1998;24:301–4. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Feldo M, Chodkowska A, Szklarczyk V, Urbanska EM. Six-week treatment with Ukrain in rabbits. Part III: Serum levels of thyroid hormones. Drugs Exp Clin Res. 1998;24:305–8. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Chodkowska A, Misztal G, Jagiello G. Preliminary pharmacokinetic studies of Ukrain in rats. Drugs Exp Clin Res. 1998;24:309–11. [PubMed]
  • Gorzelak M, Jablonski M, Patyra M, Jagiello-Wojtowicz E. Effect of intermittent three-month treatment with differnt doses of Ukrain on subregional femoral bone mineral density of sexually mature female rats. Drugs Exp Clin Res. 1998;24:313–6. [PubMed]
  • Jablonski M, Gorzelak M, Patyra M, Jagiello-Wojtowicz E. Effect of intermittent three-month treatment with different doses of Ukrain on subregional bone mineral density of the femur of ovariectomized rats. Drugs Exp Clin Res. 1998;24:317–20. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Chodkowska A, Szkodziak A, Siembida E, Gustaw K, et al. Modification of antinociceptive action of Ukrain by endogenous nitric oxide in the writhing syndrome test in mice. Drugs Exp Clin Res. 1998;24:321–5. [PubMed]
  • Jagiello-Wojtowicz E, Kleinrok Z, Gustaw K. Interaction between Ukrain and Naltrexone in the writhing syndrome test in mice. Drugs Exp Clin Res. 1998;24:327–30. [PubMed]
  • Boyko VN, Zholus RB. A comparative evaluation of the influence of the complex drug Ukrain and its components on the effects of radiation. Drugs Exp Clin Res. 1998;24:331–3. [PubMed]
  • Boyko VN, Levshina YeV. A study of the influence of a novel drug Ukrain in vivo effects of low-dose ionizing radiation. Drugs Exp Clin Res. 1998;24:339–41. [PubMed]
  • Boyko VN, Zholus RB, Legeza VI. A study of the influence of different types of radioprotectors on the survival of mice treated with ionizing radiation over a wide dose range. Drugs Exp Clin Res. 1998;24:343–7. [PubMed]
  • Hruby R. Ukrain: acute toxicity after intravenous, intramuscular and oral administration in rats. Drugs Exp Clin Res. 2000;26:157–61. [PubMed]
  • Doroshenko YM, Karavay AV, Hodysch YY, Uglyanitsa KN, Nowicky JW, Nefyodov LI. The dynamics of concentration of the main fluorescent component of Ukrain in the tissues and blood plasma of rats with W-256 tumor after a single intravenous injection. Drugs Exp Clin Res. 2000;26:171–7. [PubMed]
  • Kurochkin SN, Kolobkov SL, Votrin II, Voltchek IV. Induction of apoptosis in cultured Chinese hamster ovary cells by Ukrain and its synergistic action with etoposide. Drugs Exp Clin Res. 2000;26:275–8. [PubMed]
  • Korolenko TA, Djanayeva SJ, Falameyeva OV, Wevers RA, Filjushina EE, Buzueva II, et al. Chitotriosidase as a new marker of macrophage stimulation in a tumor model treated with cyclophosphamide and Ukrain. Drugs Exp Clin Res. 2000;26:279–83. [PubMed]
  • Korolenko TA, Poteryaeva ON, Djanayeva SJ, Svechnikova IG, Kaleidn VI, Timofeyeva OA, et al. Cystatin C in LS lymphosarcoma and HA-1 hepatoma treated with Ukrain and cyclophosphamide and involvement of apoptosis. Drugs Exp Clin Res. 2000;26:285–92. [PubMed]
  • Djanayeva SJ, Korolenko TA, Svechnikova IG, Falameyeva OV, Korolenko E, Kaledin VI, et al. Influence of Ukrain and cyclophosphamide administration on HA-1 murine hepatoma and LS lymphoma on aspartic proteinase cathepsin D. Drugs Exp Clin Res. 2000;26:293–9. [PubMed]
  • Poteryaeva ON, Falameyeva OV, Korolenko TA, Kaledin VI, Djanayeva SJ, Nowicky JW, et al. Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. Drugs Exp Clin Res. 2000;26:301–6. [PubMed]
  • Luksa-Lichtenthaler GL, Ladutko EI, Nowicky JW. Influence of Ukrain on the nuclear thyroid hormone receptors after short-term gamma-irradiation. Drugs Exp Clin Res. 2000;26:307–10. [PubMed]
  • Luksa-Lichtenthaler GL, Ladutko EI, Nowicky JW. Radiomodification effects of Ukrain, a cytostatic and immunomodulating drug, on intracellular glucocorticoid reception during short-term gamma-irradiation. Drugs Exp Clin Res. 2000;26:311–5. [PubMed]
  • Jablonski M, Korczak W, Gorzelak M, Jagiell-Wojtowicz E. Intermittent three-month treatment with Ukrain in intact and ovariectomized rats. Part III: Effect on the nativ eelectron paramagnetic resonance signal intensity of the femur. Drugs Exp Clin Res. 2000;26:333–6. [PubMed]
  • Stabuc B, Benedicic D. Ukrain with chemotherapy in malignant melanoma (case report). Drugs Exp Clin Res. 1996;22:231–3. [PubMed]
  • Hamler F, Hiesmayr W, Korsh O, Melnyk A. Ukrain monotherapy in malignant melanoma (case report). Drugs Exp Clin Res. 1996;22:235–7. [PubMed]
  • Kotsay B, Lisnyak O, Myndiuk O, Romanys-hyn J, Fabri O. Ukrain treatment of rhabdomyosarcoma (case report). Drugs Exp Clin Res. 1996;22:239–41. [PubMed]
  • Kadan P, Korsh OB, Melnyk A. Ukrain therapy of recurrent breast cancer with lung metastases (case report). Drugs Exp Clin Res. 1996;22:243–5. [PubMed]
  • Schramm E, Nowicky JW, Godysh Y. Biophysiological effects of Ukrain therapy in a patient with breast cancer (case report). Drugs Exp Clin Res. 1996;22:247–54. [PubMed]
  • Kroiss T, Melnyk A, Korsh OB. Ukrain treatment in carcinoma of the cervix (case report). Drugs Exp Clin Res. 1996;22:255–7. [PubMed]
  • Lohninger A, Korsh OB, Melnyk A. Combined therapy with Ukrain and chemotherapy in ovarian cancer (case report). Drugs Exp Clin Res. 1996;22:259–62. [PubMed]
  • Sakalo VS, Korsh OB, Melnyk A. Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report). Drugs Exp Clin Res. 1996;22:263–5. [PubMed]
  • Vyas JJ, Jain VK. Ukrain treatment in carcinoma of the oesophagus (case report). Drugs Exp Clin Res. 1996;22:267–9. [PubMed]
  • Kadan P, Korsh OB, Hiesmayr W. Ukrain in the treatment of urethral recurrent carcinoma (case report). Drugs Exp Clin Res. 1996;22:271–3. [PubMed]
  • Steinacker J, Kroiss T, Korsh OB, Melnyk A. Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report). Drugs Exp Clin Res. 1996;22:275–7. [PubMed]
  • Steinacker J, Korsh OB, Melnyk A. Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report). Drugs Exp Clin Res. 1996;22:279–81. [PubMed]
  • Voltchek IV, Liepins A, Nowicky JW, Brzosko WJ. Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma. Drugs Exp Clin Res. 1996;22:283–6. [PubMed]
  • Aschhoff B. Ukrain treatment in a patient with stage IV neuroblastoma. A case report. Drugs Exp Clin Res. 1998;24:243–5. [PubMed]
  • Nowicky JW, Staniszewski A, Zbroja-Sontag W, Slesak B, Nowicky W, Hiesmayr W. Evaluation of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. ("Ukrain") as an immunostimulant in patients with various carcinomas. Drugs Exp Clin Res. 1991;17:139–43. [PubMed]
  • Danysz A, Kokoschinegg M, Hamler F. Clinical studies of Ukrain in healthy volunteers (phase 1). Drugs Exp Clin Res. 1992;18:39–43. [PubMed]
  • Musianowycz J, Judmajer F, Manfreda D, Spangler P, Albrecht H, Hoffmann J, et al. Clinical studies of Ukrain in terminal cancer patients (phase II). Drugs Exp Clin Res. 1992;18:45–50. [PubMed]
  • Nowicky JW, Manolakis G, Meijer D, Vatanasapt V, Brzosko WJ. Ukrain both as an anti cancer and immunoregulatory agent. Drugs Exp Clin Res. 1992;18:51–4. [PubMed]
  • Danilos J, Zbroja-Sontag W, Baran E, Kurylcio L, Kondratowicz L, Jusiak L. Preliminary studies on the effect of Ukrain (Tris(2-([5bS-(5ba, 6b, 12ba)]-5b, 6, 7, 12b, 13, 14-hexahydro-13-methyl[1, 3] benzodioxolo [5, 6-v]-1-3-dioxolo [4, 5-i] phenanthridinium-6-o1]-Ethaneaminyl) Phosphinesulfide.6HCl) on the immunological response in patients with malignant tumours. Drugs Exp Clin Res. 1992;18:55–62. [PubMed]
  • Pengsaa P, Wongpratoom W, Vatanasapt V, Udomthavornsuk B, Mairieng E, Tangvorapongchai V, et al. The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky. Drugs Exp Clin Res. 1992;18:69–72. [PubMed]
  • Lohninger A, Hamler F. Chelidonium majus L. (Ukrain) in the treatment of cancer patients. Drugs Exp Clin Res. 1992;18:73–7. [PubMed]
  • Brzosko WJ, Uglyanica KN, Fomin KA, Nowicky JW. Influence of Ukrain on breast cancer. Drugs Exp Clin Res. 1996;22:127–33. [PubMed]
  • Zemskov SV, Iaremchuk OIa, Susak IaM, Deneka IeR, Kravchenko OV, Iatsyk IM. The initial experience of usig the preparation Ukrain in treating cancer patients in Ukraine. Lik Sprava. 1996;Jan-Feb:158–61.
  • Nefyodov LI, Uglyanitsa KN, Smirnov VY, Karavay AV, Brzosko WJ. Comparative evaluation of blood plasma and tumor tissue amino acid pool in radiation or neoadjuvant preoperative therapies of breast cancer with the antitumour drug Ukrain. Drugs Exp Clin Res. 2000;26:231–7. [PubMed]
  • Uglyanitsa KN, Nefyodov LI, Karayedova LM, Nowicky JW, Brzosko WJ. Clinical aspects of cancer treatment and new biochemical mechanisms of the drug Ukrain. Drugs Exp Clin Res. 2000;26:239–47. [PubMed]
  • Nefyodov LI, Uglyanica KN, Smirnov VY, Doroshenko YM, Fomin KA, Nowicky JW, et al. Amino acids and their derivatives in tumour tissue from patients with breast cancer treated with Ukrain. Part VI. Drugs Exp Clin Res. 1996;22:159–61. [PubMed]
  • Nefyodov LI, Uglyanica KN, Smirnov VY, Doroshenko YM, Fomin KA, Nowicky JW, et al. Amino acids and their derivatives in blood plasma of patients with breast cancer treated with Ukrain. Part V. Drugs Exp Clin Res. 1996;22:155–7. [PubMed]
  • Uglyanica KN, Maciuk JR, Fomin KA, Nefyodov LI, Kravchuk RI, Vinogradova LM, et al. Influence of Ukrain on patients with surgucally treated breast cancer. Part IV. Drugs Exp Clin Res. 1996;22:147–53. [PubMed]
  • Fomin KA, Uglyanica KN, Nefyodov LI, Djurd TI, Nowicky JW, Brzosko WJ, et al. Influence of Ukrain on patients with surgically treated breast cancer. Part III. The immune system. Drugs Exp Clin Res. 1996;22:143–5. [PubMed]
  • Uglyanica KN, Fomin KA, Nefyodov LI, Vilkiewich TW, Nowicky JW, Brzosko WJ, et al. Influence of Ukrain on patients with surgically treated breast cancer. Part II. Hormonal profile. Drugs Exp Clin Res. 1996;22:139–43. [PubMed]
  • Uglyanica KN, Fomin KA, Nefyodov LI, Nowicky JW, Brzosko WJ, Jankowski A. Influence of Ukrain on patients with surgically treated breast cancer. Part I. Clinical and laboratory parameters. Drugs Exp Clin Res. 1996;22:135–8. [PubMed]
  • Nefyodov LI, Uglyanitsa KN, Nechiporenko NA, Smirnov VY, Brzosko WJ, Karavay NL. New biochemical mechanisms of the anticancer effect of Ukrain in the treatment of cancer of the urinary bladder. Drugs Exp Clin Res. 2000;26:195–9. [PubMed]
  • Uglyanitsa KN, Nechiporenko NA, Nefyodov LI, Brzosko WJ. Ukrain therapy of stage T1NOMO bladder cancer patients. Drugs Exp Clin Res. 1998;24:227–30. [PubMed]
  • Uglyanica KN, Fomin KA, Nefyodov LI, Nowicky JW, Brzosko WJ, Jankowski A. Influence of Ukrain on patients with surgically treated breast cancer (introductory remarks). Drugs Exp Clin Res. 1996;22:123–5. [PubMed]
  • Uglyanitsa KN, Nefyodov LI, Doroshenko YM, Brzosko WJ. Comparison of the efficacy of different doses of Ukrain in the combined treatment of breast cancer. Drugs Exp Clin Res. 2000;26:201–21. [PubMed]
  • Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary. Controlled Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4. [PubMed] [Full Text]
  • Susak YM, Zemskov SV, Yaremchuk OY, Kravchenko OV, Yatsyk IM, Korsh OB. Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. Drugs Exp Clin Res. 1996;22:115–22. [PubMed]
  • Bondar GV, Borota AV, Yakovets YI, Zolotukhin SE. Comparative evaluation of the complex treatment of rectal cancer patients (chemotherapy and X-ray therapy, Ukrain monotherapy). Drugs Exp Clin Res. 1998;24:221–6. [PubMed]
  • Zemskov VS, Procopchuk OL, Susak YM, Zemskov SV, Hodysh YY, Zemskova MV. Ukrain (NSC-631570) in the treatment of pancreas cancer. Drugs Exp Clin Res. 2000;26:179–90. [PubMed]
  • Uglyanitsa KN, Nefyodov LI, Brzosko WJ. Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. Report I. Clinical aspects of Ukrain application. Drugs Exp Clin Res. 2000;26:223–30. [PubMed]
  • Zemskov SV, Prokopchuk O, Susak Y, Zemskov S, Tkachenko O, Hodysh Y, et al. Efficacy of Ukrain in the treatment of pancreatic cancer. Langenbecks Arch Surg. 2002;387:84–9. doi: 10.1007/s00423-002-0293-y. [PubMed] [Full Text]
  • Gansauge F, Ramadani M, Pressmar J, Gansauge S, Muehling B, Stecker K, et al. NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langenbecks Arch Surg. 2002;386:570–4. doi: 10.1007/s00423-001-0267-5. [PubMed] [Full Text]
  • Susak YM, Yaremchuk OY, Zemskov VS, Kravchenko OB, Liepins A, Yatsyk IM, et al. Randomised clinical study of Ukrain on colorectal cancer. Eur J Cancer. 1995;31:S153. doi: 10.1016/0959-8049(95)95982-C. Abstract 733.
  • Jagiello-Wojtowicz E, Kleinrok Z, Urbanska EM. Ukrain (NSC-631570) in experimental and clinical studies: a review. Drugs Exp Clin Res. 1998;24:213–9. [PubMed]

 

 


 


View My Stats